Menu
Logo

Stelara Efficacy on enthesitis

IN RWE STELARA® IS SUPERIOR TO TNF INHIBITOR TREATMENT IN RESOLVING ENTHESITIS IN PSA PATIENTS WITH ACTIVE ENTHESITIS2

RESULT

73.9% (23) of STELARA®-treated patients reached the primary endpoint (SPARCC=0) vs. 41.7% (24) of TNFi patients at 6 months

An exploratory logistic regression was applied to investigate relations of a SPARCC of 0 at 24 weeks to potential predictors such as age, gender, duration of PsA, number of swollen and tender joints (TJC68/SJC66) at baseline TJC68/SJC66), severity of psoriasis at baseline (PASI) and study treatment. Patients receiving STELARA® being more likely to show no signs of enthesitis after 6 months (OR=0.037; p=0.018).
Primary endpoint: Patients achieving SPARCC=0 after 6 months
graph-13

OR, Odds Ratio; RWE, Real World Evidence; TNF, Tumor Necrosis Factor; TNFi, Tumor Necrosis Factor Inhibitor; PSA, Psoriatic Arthritis; SPARCC, Spondyloarthritis Research Consortium of Canada.

stelara_logo

CP-179204